GlaxoSmithKline cleared for $91M flu vaccine plant in USA; Gets CRL on Q-Plan H5N1
UK pharma giant GlaxoSmithKline (LSE: GSK) and The Texas A&M University System (TAMUS) say that the US Department of Health and Human Services (DHHS) has approved the establishment of a $91 million influenza-vaccines manufacturing facility in Bryan-College Station, Texas.
The TAMUS influenza vaccines manufacturing center will eventually produce influenza vaccine based on the proprietary EB66 cell-culture line and complement GSK’s existing influenza vaccines operations, based in Quebec, Canada, and Dresden, Germany.
GSK's operations hub in Marietta, Pennsylvania, will package, inspect and distribute influenza vaccine manufactured at the Texas A&M Center. The exclusive license for the use of EB66 cell line was obtained from Vivalis by GSK Biologicals for the field of Influenza and sublicensed use at the Texas A&M Center.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze